Ken Berlin Email Address

President, Chief Executive Officer and Board Member

Advaxis is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious diseases.

Mr. Kenneth A. Berlin, also known as Ken, J.D., serves as President, Chief Executive Officer and Director of Advaxis, Inc. since April 23, 2018. He served as the Chief Executive Officer and President of Rosetta Genomics, Ltd. since November 2, 2009 until April 18, 2018. Mr. Berlin served as a Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex LLC, a Johnson & Johnson company. Mr. Berlin began his career as an attorney at Simpson ... Thacher & Bartlett in New York City. Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. He led and participated on the legal team that oversaw several mergers, acquisitions, divestitures and commercial transactions across Johnson & Johnson. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 to 2004, Mr. Berlin served as Vice President of licensing and new business development in the pharmaceuticals group and from 2004 to 2007 served as Worldwide Vice President, franchise development Ortho-Clinical Diagnostics. He served as a Director of Rosetta Genomics Ltd. from December 2009 to March 2011. He has received several awards including the 2004 Pharmaceutical Achievement Award--Licensing Deal of the Year Finalist. He is a member of the board of directors of the Central and South Jersey Chapter of Susan G. Komen for the Cure. During Mr. Berlin's tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch(R) technology in the fight against cancer. Mr. Berlin holds an A.B. Degree from Princeton University and a J.D. from the University of California Los Angeles School of Law.